Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 76.98
NBIX's Cash to Debt is ranked higher than
86% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.43 vs. NBIX: 76.98 )
NBIX' s 10-Year Cash to Debt Range
Min: 1.72   Max: No Debt
Current: 76.98

Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
79% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.95 vs. NBIX: No Debt )
NBIX' s 10-Year Interest Coverage Range
Min: 2.5   Max: 9999.99
Current: No Debt

2.5
9999.99
F-Score: 2
Z-Score: 42.59
M-Score: -7.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -3802.12
NBIX's Operating margin (%) is ranked lower than
54% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.41 vs. NBIX: -3802.12 )
NBIX' s 10-Year Operating margin (%) Range
Min: -17340.03   Max: 43.82
Current: -3802.12

-17340.03
43.82
Net-margin (%) -3546.26
NBIX's Net-margin (%) is ranked lower than
54% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.06 vs. NBIX: -3546.26 )
NBIX' s 10-Year Net-margin (%) Range
Min: -16936.19   Max: 48.53
Current: -3546.26

-16936.19
48.53
ROE (%) -27.01
NBIX's ROE (%) is ranked higher than
54% of the 876 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. NBIX: -27.01 )
NBIX' s 10-Year ROE (%) Range
Min: -250.63   Max: 94.61
Current: -27.01

-250.63
94.61
ROA (%) -22.95
NBIX's ROA (%) is ranked higher than
54% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.17 vs. NBIX: -22.95 )
NBIX' s 10-Year ROA (%) Range
Min: -62.22   Max: 26.57
Current: -22.95

-62.22
26.57
ROC (Joel Greenblatt) (%) -2819.04
NBIX's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.06 vs. NBIX: -2819.04 )
NBIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2323.57   Max: 2175.88
Current: -2819.04

-2323.57
2175.88
Revenue Growth (3Y)(%) -60.10
NBIX's Revenue Growth (3Y)(%) is ranked lower than
51% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. NBIX: -60.10 )
NBIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -76.6   Max: 175.9
Current: -60.1

-76.6
175.9
EBITDA Growth (3Y)(%) 47.00
NBIX's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.50 vs. NBIX: 47.00 )
NBIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.4   Max: 111.1
Current: 47

-64.4
111.1
EPS Growth (3Y)(%) 66.30
NBIX's EPS Growth (3Y)(%) is ranked higher than
96% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NBIX: 66.30 )
NBIX' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.8   Max: 66.3
Current: 66.3

-69.8
66.3
» NBIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NBIX Guru Trades in Q4 2013

Pioneer Investments 524,523 sh (+10.55%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q1 2014

NBIX Guru Trades in Q1 2014

Pioneer Investments 434,514 sh (-17.16%)
» More
Q2 2014

NBIX Guru Trades in Q2 2014

Pioneer Investments 511,617 sh (+17.74%)
» More
Q3 2014

NBIX Guru Trades in Q3 2014

Pioneer Investments 503,938 sh (-1.5%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-09-30 Sold Out 0.03%$10.6 - $16.7 $ 33.66144%0
George Soros 2013-06-30 New Buy0.03%$10.9 - $13.57 $ 33.66174%200000
Joel Greenblatt 2012-12-31 Sold Out 0.13%$6.88 - $8.66 $ 33.66343%0
Joel Greenblatt 2012-06-30 Add 23.8%0.03%$6.31 - $8.06 $ 33.66369%259903
George Soros 2012-06-30 Sold Out 0.02%$6.31 - $8.06 $ 33.66369%0
Joel Greenblatt 2012-03-31 New Buy0.15%$7.33 - $9.79 $ 33.66323%209930
George Soros 2012-03-31 New Buy0.02%$7.33 - $9.79 $ 33.66323%150000
George Soros 2011-12-31 Sold Out 0.0018%$5.5 - $8.58 $ 33.66398%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.60
NBIX's P/B is ranked higher than
54% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NBIX: 11.60 )
NBIX' s 10-Year P/B Range
Min: 0.9   Max: 108
Current: 11.6

0.9
108
P/S 3415.30
NBIX's P/S is ranked higher than
53% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. NBIX: 3415.30 )
NBIX' s 10-Year P/S Range
Min: 3.15   Max: 3435
Current: 3415.3

3.15
3435
EV-to-EBIT -44.26
NBIX's EV-to-EBIT is ranked lower than
56% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.35 vs. NBIX: -44.26 )
NBIX' s 10-Year EV-to-EBIT Range
Min: -165.7   Max: 426.3
Current: -44.26

-165.7
426.3
Current Ratio 13.09
NBIX's Current Ratio is ranked higher than
95% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. NBIX: 13.09 )
NBIX' s 10-Year Current Ratio Range
Min: 1.63   Max: 24.56
Current: 13.09

1.63
24.56
Quick Ratio 13.09
NBIX's Quick Ratio is ranked higher than
96% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. NBIX: 13.09 )
NBIX' s 10-Year Quick Ratio Range
Min: 1.63   Max: 24.56
Current: 13.09

1.63
24.56
Days Sales Outstanding 730.25
NBIX's Days Sales Outstanding is ranked higher than
56% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.21 vs. NBIX: 730.25 )
NBIX' s 10-Year Days Sales Outstanding Range
Min: 2.53   Max: 149.47
Current: 730.25

2.53
149.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.50
NBIX's Price/Net Cash is ranked higher than
89% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. NBIX: 17.50 )
NBIX' s 10-Year Price/Net Cash Range
Min: 2.62   Max: 254.67
Current: 17.5

2.62
254.67
Price/Net Current Asset Value 17.50
NBIX's Price/Net Current Asset Value is ranked higher than
83% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. NBIX: 17.50 )
NBIX' s 10-Year Price/Net Current Asset Value Range
Min: 2.56   Max: 103.76
Current: 17.5

2.56
103.76
Price/Tangible Book 11.40
NBIX's Price/Tangible Book is ranked higher than
62% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. NBIX: 11.40 )
NBIX' s 10-Year Price/Tangible Book Range
Min: 1.11   Max: 101.67
Current: 11.4

1.11
101.67
Price/DCF (Projected) 88.60
NBIX's Price/DCF (Projected) is ranked higher than
73% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.88 vs. NBIX: 88.60 )
NBIX' s 10-Year Price/DCF (Projected) Range
Min: 9.63   Max: 55.55
Current: 88.6

9.63
55.55
Price/Median PS Value 168.30
NBIX's Price/Median PS Value is ranked higher than
54% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. NBIX: 168.30 )
NBIX' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 80.35
Current: 168.3

0.19
80.35
Earnings Yield (Greenblatt) -2.30
NBIX's Earnings Yield (Greenblatt) is ranked higher than
58% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. NBIX: -2.30 )
NBIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.3   Max: 3683.9
Current: -2.3

-2.3
3683.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NB3.Germany,
Neurocrine Biosciences, Inc., a California corporation was incorporated in January 1992 and was reincorporated in Delaware in May 1996. The Company discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. Its product candidates address pharmaceutical markets internationally, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company's two late-stage clinical programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II clinical studies of uterine fibroids that is partnered with AbbVie, and a wholly owned VMAT2 inhibitor for the treatment of movement disorders that is currently in Phase II development. Its clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids. The Company faces competition from biotechnology and pharmaceutical companies, research institutions, government agencies and academic institutions.
» More Articles for NBIX

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,650 Shares Mar 03 2010 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares Mar 03 2010 

More From Other Websites
Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic... Jan 20 2015
Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic... Jan 20 2015
Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal... Jan 16 2015
Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal... Jan 16 2015
US STOCKS-Wall St jumps for 2nd day, helped by economic optimism Jan 08 2015
US STOCKS-Wall St jumps for 2nd day, helped by economic optimism Jan 08 2015
US STOCKS-Wall St jumps for 2nd day, helped by economic optimism Jan 08 2015
US STOCKS-Wall St up more than 1 pct for 2nd day; Fed, ECB lift Jan 08 2015
US STOCKS-Wall St up more than 1 pct for 2nd day; Fed, ECB lift Jan 08 2015
NBIX: AbbVie, Neurocrine Report Positive Data With Elagolix In Phase 3 Violet Petal Study Jan 08 2015
Midday movers: Apple, Ford Motor, Yahoo & more Jan 08 2015
Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015
Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015
AbbVie, Neurocrine drug successful in endometriosis trial Jan 08 2015
AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix... Jan 08 2015
What Investors Expect From Neurocrine Biosciences' Next Drug Announcement Jan 02 2015
ASPX: Auspex Pharma Hits A Homerun In Phase 3 Huntington's Chorea Trial Dec 17 2014
Neurocrine draws bearish trade Dec 11 2014
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline Dec 10 2014
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK